tv-1106
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01811576)
Timeline
Indications
Studied for
Mechanism of action
- Hepatitis B virusImmunity, passive
Hepatitis B virus immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- tv-1106
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02410343 | Phase 3 | Apr 1, 2015 | Teva |
| NCT02410356 | Phase 3 | Apr 1, 2015 | Teva |
| NCT02092077 | Phase 2 | Apr 1, 2014 | Teva |
| NCT01811576 | Phase 2 | Mar 1, 2013 | Teva |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 4 | 4 | 2 | 2013 |
1 organizations
Page 1 / 1